78
Participants
Start Date
October 31, 2003
Primary Completion Date
October 31, 2009
Study Completion Date
October 31, 2009
Thalidomide
100 mg PO (by mouth) daily for 8 weeks
CPT-11
125 mg/m\^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest
MRI Scan
Dynamic MRI scan with dye injection through vein, every 6 weeks
Quantitative Sensory Tests (QST)
QST, every 12 weeks, to check for any nerve problems that may be present before starting treatment; by touching a small machine tests are done on feeling of touch, vibration, and temperature.
U.T.M.D. Anderson Cancer Center, Houston
Collaborators (1)
Celgene Corporation
INDUSTRY
M.D. Anderson Cancer Center
OTHER